Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Omega 7 Oil and Inflammatory Biomarker Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03669575
Recruitment Status : Completed
First Posted : September 13, 2018
Last Update Posted : October 15, 2019
Sponsor:
Information provided by (Responsible Party):
Bastyr University

Tracking Information
First Submitted Date  ICMJE August 10, 2018
First Posted Date  ICMJE September 13, 2018
Last Update Posted Date October 15, 2019
Actual Study Start Date  ICMJE September 1, 2017
Actual Primary Completion Date June 30, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 12, 2018)
  • CRP (serum) [ Time Frame: 3 weeks ]
    Quantification of the serum hsCRP level during active supplement
  • Pain/discomfort (self-assessment from 1 - 10) [ Time Frame: 3 weeks ]
    The self-reported level of the musculoskeletal pain/discomfort during active supplement
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 12, 2018)
  • Omega 7 (plasma) [ Time Frame: 3 weeks ]
    Quantification of the plasma palmitolenic acid (major omega 7 fatty acid) level during the active supplementation
  • IL-6 (plasma) [ Time Frame: 3 weeks ]
    Quantification of the plasma IL-6 level during the active supplementation
  • TNFalpha (plasma) [ Time Frame: 3 weeks ]
    Quantification of the plasma TNFalpha level during the active supplementation
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Omega 7 Oil and Inflammatory Biomarker Study
Official Title  ICMJE Modulation of Inflammatory Makers by the Supplementation of n7FA for 3 wk, Randomized Placebo Controlled Crossover Study
Brief Summary The purpose of the study is to determine whether the palmitoleic acid supplementation can reduce the serum inflammatory biomarkers and low quality of life scores due to musculoskeletal discomfort. The study design is a 2-arm placebo-controlled double blind crossover trial. The randomized sequence of a single crossover is divided into 1:1 and each supplementation is three weeks with no washout in between.
Detailed Description

The purpose of the study is to investigate whether or not the supplementation of a particular omega-7 fatty acid decreases the serum biomarkers of inflammation, i.e. highly sensitive C-reactive protein, TNF-alpha and IL-6 of participants who have been experiencing decreased quality of life (QOL) and having elevated these serum markers. The study is placebo-controlled and conducted in a double blinded manner. Participants will be crossed over on supplements (active and placebo) in a random sequence. The total length of a trial is six weeks in which the participants will be asked to maintain stable diet. The baseline blood draw, physical exam, range of motion, QOL and dietary assessment and taking vitals are performed. After the blood test results and/or QOL assessment confirm the eligibility, three weeks supply of the investigational supplement will be mailed or picked up in person. The supplementation is one gel-capusule a day for three weeks. At the end of three weeks, another blood draw, physical exam, range of motion, and QOL assessment are conducted; then the other investigational supplement will be provided. The assessment of the second supplement will occur after another three-week mark. If no adverse reaction is observed and there is no concerns, the participant will be exited from the study.

The goal of enrollment is 50 participants who are between 18 to 99 years old with decreased quality of life and potentially elevated serum markers of inflammation. Volunteers will be randomized by a block of four so at any given moment, one group does not exceed more than three participants. The study takes place at Kenmore campus.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:
Eligible participants are randomly assigned to one of two crossover arms, i.e verum-placebo or placebo-verum sequence. The verum groups are dosed approximately 900 mg a day omega-7 fatty acid, and placebo group contains other fatty acids except for omega-7. After the baseline assessment, a participant is on the supplement bottle for three weeks before re-assessed, and starts the second bottle without a washout period. The participant is re-assessed at the end of the six weeks before exits the study.
Masking: Double (Participant, Investigator)
Masking Description:
The randomization block of four. Participants, research coordinators, and study clinicians are blinded.
Primary Purpose: Treatment
Condition  ICMJE Musculoskeletal Pain
Intervention  ICMJE
  • Dietary Supplement: omega 7
    Three weeks omega 7 fatty acid nutritional supplement, approximately 900 mg/day
  • Dietary Supplement: Placebo
    Three weeks placebo fatty acids approximately 900 mg/day which does not contain omega 7
Study Arms  ICMJE
  • Experimental: omega 7 - placebo
    Receiving the active first then switch to the placebo after three weeks
    Interventions:
    • Dietary Supplement: omega 7
    • Dietary Supplement: Placebo
  • Active Comparator: placebo - omega 7
    Receiving the placebo first then switch to the active after three weeks
    Interventions:
    • Dietary Supplement: omega 7
    • Dietary Supplement: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 14, 2019)
56
Original Estimated Enrollment  ICMJE
 (submitted: September 12, 2018)
50
Actual Study Completion Date  ICMJE October 1, 2019
Actual Primary Completion Date June 30, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria: (any of the below)

  • baseline CRP 1.0 mg/L or higher
  • > 3 months (chronic) musculoskeletal pain/discomfort, which the participant is able to monitor during the course of trial (6 weeks)

Exclusion Criteria:

  • Taking narcotic or opioid pain medication
  • Unable to monitor NSAID or OTC pain medication quantity
  • Unable to visit Kenmore Washington Clinical Research Center for three times
  • Objection from his/her primary care doctor
  • Employee or family member of Barlines Organics
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03669575
Other Study ID Numbers  ICMJE 16-1575
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Bastyr University
Study Sponsor  ICMJE Bastyr University
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Masa Sasagawa, ND, PhD Bastyr University
PRS Account Bastyr University
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP